Risk of CVD or type-2 diabetes according to change in BMI after starting ART
1 October 2014. Related: Conference reports, Antiretrovirals, Side effects.
Antiretrovirals
Single-pill dolutegravir/abacavir/3TC (Triumeq) approved in EU and US
1 October 2014. Related: Antiretrovirals.
Cobicistat and elvitegravir approved in the US as single pills
1 October 2014. Related: Antiretrovirals.
Positive opinion to approve of darunavir/cobicistat in Europe
1 October 2014. Related: Antiretrovirals.
Pill A, Pill B: simplified second-line treatment for low-income countries
1 August 2014. Related: Conference reports, Antiretrovirals, Treatment access.
Update on paediatric antiretrovirals
1 August 2014. Related: Conference reports, Antiretrovirals, Paediatric care.
Is d4T a viable option for children in low-income countries?
1 August 2014. Related: Conference reports, Antiretrovirals, Paediatric care.
Short-term safety of atazanavir/ritonavir-based second line treatment in Zambia
1 August 2014. Related: Conference reports, Antiretrovirals.
Uptake of ART is influenced by distance to the health facility in rural Zambia
1 August 2014. Related: Conference reports, Antiretrovirals, Pregnancy.
Dolutegravir-based single-tablet regimen set for EU approval
1 August 2014. Related: Antiretrovirals.
The antiretroviral pipeline 2014
19 July 2014. Related: Pipeline report, Antiretrovirals.
The paediatric antiretroviral pipeline
19 July 2014. Related: Pipeline report, Antiretrovirals, Paediatric care.
Preventive technologies: antiretroviral and vaccine development
19 July 2014. Related: Pipeline report, Antiretrovirals, HIV prevention and transmission, Vaccines and microbicides.
50% of UK seroconverters start ART within 1.4 years of infection: treating during primary infection should be a patient choice
27 May 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
PIVOT study: further analysis from five-year PI/r monotherapy strategy study
27 May 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
Pharmacokinetics of antiretrovirals in pregnancy
27 May 2014. Related: Conference reports, Antiretrovirals, Pregnancy.
Better virologic outcomes with efavirenz vs lopinavir/ritonavir in pregnant women and no difference in risk of preterm birth
27 May 2014. Related: Conference reports, Antiretrovirals, Pregnancy.
Once daily lopinavir/ritonavir not recommended for routine use in children and adolescents
27 May 2014. Related: Conference reports, Antiretrovirals, Paediatric care.
Early antiretroviral treatment in infants
27 May 2014. Related: Conference reports, Antiretrovirals, Paediatric care.
ARV pipeline: doravirine, GSK-744 and BMS-068
24 March 2014. Related: Conference reports, Antiretrovirals.
Viral load rebound rate of 35% using ritonavir-boosted PI monotherapy: results of five-year PIVOT study
24 March 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
Dual therapy less effective at high viral load: NEAT 001 study with raltegravir/darunavir/r
24 March 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
Atazanavir, raltegravir and darunavir virologically equivalent in naive patients but significant differences for tolerability: results from ACTG 5257
24 March 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
Pharmacokinetic targets for efavirenz might be too high
24 March 2014. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Women, HIV research and antiretrovirals
1 February 2014. Related: Conference reports, Antiretrovirals, Women's health, Cure-related research.
Outcomes in infants exposed to lopinavir/ritonavir in utero
1 February 2014. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
Two percent rate of efavirenz discontinuation in an ART programme in Malawi
1 February 2014. Related: Conference reports, Antiretrovirals, Pregnancy, Side effects.
Dolutegravir approved in Europe
1 February 2014. Related: Antiretrovirals, Treatment access.
Dolutegravir superior to darunavir/r at week 48 in open label treatment naïve study
1 December 2013. Related: Conference reports, Antiretrovirals.
GSK744: 24-week results with oral integrase inhibitor planned for once-monthly injections
1 December 2013. Related: Conference reports, Antiretrovirals.
Cenicriviroc: 48 week results compared to efavirenz
1 December 2013. Related: Conference reports, Antiretrovirals.
Approaches to once-daily raltegravir: new formulation likely to require food
1 December 2013. Related: Conference reports, Antiretrovirals.
DSMB stops boosted atazanavir monotherapy study due to virological failure
1 December 2013. Related: Conference reports, Antiretrovirals.
Recreational drug use is common in HIV positive gay men and is extensive in a significant minority
1 December 2013. Related: Conference reports, Antiretrovirals.
Elvitegravir approved in EU: data on food and drug interactions
1 December 2013. Related: Antiretrovirals.
ViiV file 572-trii fixed dose combination in the US: positive opinion to approve dolutegravir in the EU
1 December 2013. Related: Antiretrovirals.
Raltegravir safe and effective in pregnancy in small French study
1 October 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Side effects common but mostly mild in women taking higher dose protease inhibitors in pregnancy
1 October 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Good safety profile with long-acting integrase inhibitor GSK744
1 October 2013. Related: Conference reports, Antiretrovirals.
TAF comparable to TDF in once-daily pill for ART-naive: 48-week results
1 October 2013. Related: Conference reports, Antiretrovirals.
Dolutegravir superior to darunavir at 48 weeks in open-label ART-naive trial
1 October 2013. Related: Conference reports, Antiretrovirals.
High prices for antiretrovirals in middle-income countries outside Africa
1 October 2013. Related: Conference reports, Antiretrovirals, Treatment access.
Comparable efficacy and pregnancy outcomes with boosted atazanavir and lopinavir at standard doses
1 October 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
PrEP gives little extra benefit in attempted conception if male partner is on ART
1 October 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Cobicistat approved as pharmacokinetic (PK) booster for atazanavir and darunavir in EU prior to the US
1 October 2013. Related: Antiretrovirals.
NHS England approves four-in-one Stribild (Quad) for limited use
1 October 2013. Related: Antiretrovirals.
Dolutegravir approved in the US
1 October 2013. Related: Antiretrovirals.
ViiV goes for gold: US premium pricing may make dolutegravir redundant in the UK
1 October 2013. Related: Antiretrovirals.
From sky high to CHAI* – what needs to be done about dolutegravir pricing?
1 October 2013. Related: Antiretrovirals, Treatment access.
Pharmacokinetics of etravirine with once-daily and twice-daily dosing
1 October 2013. Related: Antiretrovirals, PK and drug interactions.
Efavirenz at 400 mg compared to standard 600 mg dose has similar efficacy with fewer side effects
25 July 2013. Related: Conference reports, Antiretrovirals.
Dolutegravir update: drug resistance in people who are treatment-naive and -experienced
25 July 2013. Related: Conference reports, Antiretrovirals, Drug resistance.
Elvitegravir/cobicisat/tenofovir/FTC: Stribild studies at IAS 2013
25 July 2013. Related: Conference reports, Antiretrovirals.
Non-standard combinations: NRTI-sparing combinations
25 July 2013. Related: Conference reports, Antiretrovirals.
High loss to follow up among asymptomatic women starting ART in pregnancy in Option B+
25 July 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Decreased growth in ART exposed uninfected infants in Botswana
25 July 2013. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
Antiretrovirals, doses and formulations for children
25 July 2013. Related: Conference reports, Antiretrovirals, Paediatric care.
Higher intracellular concentrations with tenofovir alafenamide (TAF) overcomes K65R and other key NRTI resistance in vitro
25 July 2013. Related: Conference reports, Antiretrovirals, Drug resistance.
Tentative phenotypic cut offs for dolutegravir: guidance for use with integrase resistance
25 July 2013. Related: Conference reports, Antiretrovirals, Drug resistance.
S/GSK744 and long-acting formulation indicate broadly similar resistance profile to dolutegravir
25 July 2013. Related: Conference reports, Antiretrovirals, Drug resistance.
Community request Gilead to study and develop separate formulation of new tenofovir prodrug
25 July 2013. Related: Antiretrovirals, Treatment access.
Executive summary and research policy recommendations
30 June 2013. Related: Pipeline report, Antiretrovirals, Treatment strategies, Diagnostics, Hepatitis coinfection, TB coinfection.
The antiretroviral pipeline 2013
30 June 2013. Related: Pipeline report, Antiretrovirals.
The paediatric antiretroviral pipeline
30 June 2013. Related: Pipeline report, Antiretrovirals, Paediatric care.
Small increase in birth defects in the French Perinatal Cohort
29 May 2013. Related: Conference reports, Antiretrovirals, Pregnancy.